Pharmacokinetics - USMLE Step 1

1. A 58-year-old woman with epilepsy is stable on oral phenytoin with a total phenytoin concentration of 12 mcg/mL (therapeutic 10–20). She starts oral fluconazole for candidiasis. One week later she develops nystagmus and ataxia. Labs: total phenytoin 22 mcg/mL, albumin 4.0 g/dL, creatinine 0.9 mg/dL, AST 30 U/L. Phenytoin is hepatically metabolized and exhibits capacity-limited (zero-order) elimination at higher concentrations; small dose changes can cause disproportionate concentration increases. Which of the following best describes how the pharmacokinetics of phenytoin is altered in this patient?
   Answer: Enzyme inhibition reduces metabolic clearance, increasing steady-state concentration disproportionately This question tests the application of pharmacokinetics in clinical scenarios, specifically understanding how pharmacokinetic parameters affect drug dosing and efficacy. Pharmacokinetics involves absorption, distribution, metabolism, and excretion (ADME) of drugs. Key parameters include half-life, volume of distribution, and clearance. In this case, phenytoin toxicity from fluconazole interaction results from enzyme inhibition, illustrating nonlinear kinetics amplification. The correct answer, A, is based on reduced clearance causing disproportionate concentration rise, showing saturation effects. A common misconception is enzyme induction increasing clearance, as seen in B, which fails because fluconazole inhibits CYP enzymes. To teach this, focus on zero-order elimination. Encourage students to interpret levels in nonlinear scenarios.
2. A 72-year-old man with heart failure and CKD stage 3 is taking digoxin for rate control. He presents with nausea, yellow-green vision changes, and frequent premature ventricular contractions. Labs: creatinine 1.9 mg/dL, estimated GFR 35 mL/min/1.73 m$^2$, potassium 3.1 mmol/L, magnesium 1.5 mg/dL, digoxin level 2.6 ng/mL (therapeutic 0.5–0.9). Digoxin has Vd $\approx 7\ \text{L/kg}$ and is primarily renally cleared; normal half-life is ~36 hours, longer in renal impairment. What adjustment to the dosing regimen is most appropriate given the pharmacokinetic data?
   Answer: Decrease the maintenance dose and/or extend the dosing interval due to reduced renal clearance This question tests the application of pharmacokinetics in clinical scenarios, specifically understanding how pharmacokinetic parameters affect drug dosing and efficacy. Pharmacokinetics involves absorption, distribution, metabolism, and excretion (ADME) of drugs. Key parameters include half-life, volume of distribution, and clearance. In this case, digoxin toxicity in CKD stems from accumulation, illustrating prolonged half-life from reduced renal clearance. The correct answer, B, is based on decreasing dose or interval to prevent toxicity, showing adjustment needs. A common misconception is increasing dose for reduced distribution, as seen in A, which fails because Vd is unchanged in CKD. To teach this, focus on renal dosing principles. Encourage students to monitor levels and electrolytes.
3. A 46-year-old man is treated with intravenous theophylline for severe asthma exacerbation and then placed on a continuous infusion. Theophylline has a narrow therapeutic index, hepatic metabolism, Vd $\approx 0.5\ \text{L/kg}$, and normal half-life ~8 hours. Concentrations are checked during infusion and rise gradually toward a plateau. The clinician recalls that time to reach steady state depends primarily on half-life, not on dose. Which of the following best describes the relationship between half-life and time to steady state for this drug?
   Answer: Time to steady state is approximately 4–5 half-lives, regardless of infusion rate This question tests the application of pharmacokinetics in clinical scenarios, specifically understanding how pharmacokinetic parameters affect drug dosing and efficacy. Pharmacokinetics involves absorption, distribution, metabolism, and excretion (ADME) of drugs. Key parameters include half-life, volume of distribution, and clearance. In this case, theophylline infusion reaches plateau over time, illustrating steady-state dependence on half-life. The correct answer, A, is based on steady state taking 4-5 half-lives, showing timing independence from dose. A common misconception is steady state decreasing with longer half-life, as seen in B, which fails because longer half-life delays steady state. To teach this, focus on accumulation kinetics. Encourage students to simulate infusion profiles.
4. A 65-year-old woman with CKD stage 3 is treated with a renally eliminated antibiotic that follows first-order kinetics. The drug's normal clearance is 100 mL/min and half-life 4 hours when GFR is normal. Her measured creatinine clearance is 50 mL/min, and hepatic function is normal. Assuming Vd is unchanged, the team estimates new clearance and half-life to guide dosing. Which of the following best describes how the pharmacokinetics of this drug is altered in this patient?
   Answer: Clearance decreases roughly in proportion to creatinine clearance, increasing half-life and AUC This question tests the application of pharmacokinetics in clinical scenarios, specifically understanding how pharmacokinetic parameters affect drug dosing and efficacy. Pharmacokinetics involves absorption, distribution, metabolism, and excretion (ADME) of drugs. Key parameters include half-life, volume of distribution, and clearance. In this case, antibiotic in CKD shows altered elimination, illustrating clearance proportional to GFR. The correct answer, A, is based on decreased clearance increasing half-life and AUC, showing dosing adjustment needs. A common misconception is increased clearance from hepatic compensation, as seen in B, which fails because the drug is renally eliminated. To teach this, focus on clearance estimation from CrCl. Encourage students to predict half-life changes.
5. A 55-year-old woman with alcohol-associated cirrhosis (Child-Pugh C) is treated for anxiety with oral diazepam. She reports progressive daytime somnolence after 5 days on a typical outpatient dose. Exam shows asterixis and mild confusion. Labs: total bilirubin 4.0 mg/dL, albumin 2.6 g/dL, INR 1.9, AST 110 U/L, ALT 70 U/L, creatinine 0.8 mg/dL. Diazepam is highly lipophilic with large Vd ($\approx 1.0\ \text{L/kg}$), high plasma protein binding, and primarily hepatic oxidative metabolism to active metabolites; normal half-life is 30–50 hours. A trough concentration drawn before the next dose is higher than expected for the prescribed regimen. The clinician recalls that reduced hepatic metabolism decreases clearance and prolongs half-life, and that time to steady state increases with longer half-life. What adjustment to the dosing regimen is most appropriate given the pharmacokinetic data?
   Answer: Decrease the dose and/or extend the dosing interval to account for reduced clearance This question tests the application of pharmacokinetics in clinical scenarios, specifically understanding how pharmacokinetic parameters affect drug dosing and efficacy. Pharmacokinetics involves absorption, distribution, metabolism, and excretion (ADME) of drugs. Key parameters include half-life, volume of distribution, and clearance. In this case, the patient with severe cirrhosis develops diazepam toxicity from prolonged half-life and accumulation, illustrating reduced hepatic clearance in liver disease. The correct answer, B, is based on decreasing dose or extending interval to match reduced clearance, showing how to prevent oversedation. A common misconception is increasing frequency to hasten steady state, as seen in A, which fails because longer half-life delays steady state regardless. To teach this, focus on half-life prolongation in cirrhosis and dosing adjustments. Encourage students to use therapeutic monitoring and simulate accumulation scenarios.
6. A 64-year-old woman with CKD stage 4 is started on intravenous vancomycin for MRSA bacteremia. Weight 80 kg. Labs: creatinine 2.4 mg/dL, estimated GFR 24 mL/min/1.73 m$^2$, AST 22 U/L. Vancomycin has Vd $\approx 0.7\ \text{L/kg}$ and is primarily eliminated unchanged by the kidneys; therapeutic monitoring targets an AUC/MIC goal. After a standard regimen, a measured trough concentration is 28 mcg/mL (goal often 10–20 depending on indication), suggesting accumulation. What adjustment to the dosing regimen is most appropriate given the pharmacokinetic data?
   Answer: Reduce total daily dose by lowering dose and/or extending interval due to decreased renal clearance This question tests the application of pharmacokinetics in clinical scenarios, specifically understanding how pharmacokinetic parameters affect drug dosing and efficacy. Pharmacokinetics involves absorption, distribution, metabolism, and excretion (ADME) of drugs. Key parameters include half-life, volume of distribution, and clearance. In this case, high vancomycin trough in CKD indicates accumulation, illustrating reduced renal clearance. The correct answer, B, is based on reducing dose or extending interval, showing how to achieve target AUC. A common misconception is increasing frequency to lower AUC, as seen in A, which fails because it would worsen accumulation. To teach this, focus on TDM in renal impairment. Encourage students to calculate AUC from troughs.
7. A 48-year-old man with cirrhosis from nonalcoholic steatohepatitis is started on oral propranolol for portal hypertension prophylaxis. He develops lightheadedness and bradycardia after the first few doses. Exam: HR 48/min, BP 92/54 mm Hg. Labs: total bilirubin 3.1 mg/dL, albumin 2.8 g/dL, INR 1.7, creatinine 1.0 mg/dL. Propranolol undergoes extensive first-pass hepatic metabolism with low oral bioavailability in healthy adults; Vd $\approx 4\ \text{L/kg}$ and half-life $\approx 3$–6 hours. In cirrhosis, first-pass metabolism is reduced, increasing systemic exposure after oral dosing. Which of the following best describes how the pharmacokinetics of propranolol is altered in this patient?
   Answer: Oral bioavailability increases due to reduced first-pass metabolism, raising AUC at the same dose This question tests the application of pharmacokinetics in clinical scenarios, specifically understanding how pharmacokinetic parameters affect drug dosing and efficacy. Pharmacokinetics involves absorption, distribution, metabolism, and excretion (ADME) of drugs. Key parameters include half-life, volume of distribution, and clearance. In this case, the cirrhotic patient experiences propranolol toxicity from increased systemic exposure, illustrating reduced first-pass metabolism in liver disease. The correct answer, A, is based on increased oral bioavailability raising AUC, showing why bradycardia occurs at standard doses. A common misconception is decreased bioavailability from impaired absorption, as seen in B, which fails because cirrhosis primarily affects metabolism, not absorption for this drug. To teach this, focus on first-pass effects and bioavailability changes. Encourage students to compare oral vs. IV kinetics in hepatic impairment.
8. A 24-year-old woman with epilepsy is started on intravenous phenytoin for status epilepticus and then transitioned to oral maintenance dosing. Therapeutic drug monitoring is performed. Phenytoin has Vd $\approx 0.7\ \text{L/kg}$ and is highly protein-bound; at therapeutic levels, elimination can approach capacity-limited kinetics. A concentration-time curve after IV loading shows an initial steep decline followed by a slower decline; later, small dose increases produce large concentration increases. Which pharmacokinetic parameter is most affected as phenytoin concentrations approach metabolic saturation?
   Answer: Clearance decreases as enzymes saturate, causing a disproportionate rise in steady-state concentration This question tests the application of pharmacokinetics in clinical scenarios, specifically understanding how pharmacokinetic parameters affect drug dosing and efficacy. Pharmacokinetics involves absorption, distribution, metabolism, and excretion (ADME) of drugs. Key parameters include half-life, volume of distribution, and clearance. In this case, phenytoin kinetics show saturation effects, illustrating capacity-limited elimination. The correct answer, A, is based on decreased clearance at saturation causing nonlinear rises, showing monitoring importance. A common misconception is increased Vd speeding elimination, as seen in B, which fails because saturation affects clearance, not Vd. To teach this, focus on Michaelis-Menten kinetics. Encourage students to plot concentration-dose relationships.
9. A 33-year-old woman receives a single IV bolus of a new antibiotic. Plasma concentrations are measured: 8 mg/L at 1 hour, 4 mg/L at 5 hours, and 2 mg/L at 9 hours. The drug follows first-order elimination with one-compartment kinetics and Vd $\approx 20\ \text{L}$. No renal or hepatic disease is present. Based on these data, which pharmacokinetic parameter is most directly estimated from the slope of the log concentration vs time relationship?
   Answer: Elimination rate constant ($k$), which determines half-life via $t_{1/2}=0.693/k$ This question tests the application of pharmacokinetics in clinical scenarios, specifically understanding how pharmacokinetic parameters affect drug dosing and efficacy. Pharmacokinetics involves absorption, distribution, metabolism, and excretion (ADME) of drugs. Key parameters include half-life, volume of distribution, and clearance. In this case, antibiotic concentration decline follows first-order kinetics, illustrating exponential elimination. The correct answer, A, is based on k determining half-life from log-plot slope, showing direct estimation. A common misconception is bioavailability determining IV AUC, as seen in B, which fails because F=1 for IV. To teach this, focus on one-compartment models. Encourage students to calculate k from data points.
10. A 52-year-old man with cirrhosis is prescribed an oral drug with high first-pass metabolism and low baseline bioavailability (F ~0.2). He has no renal impairment. After initiation, measured plasma concentrations are substantially higher than predicted. Labs: bilirubin 4.5 mg/dL, albumin 2.7 g/dL, INR 1.9. The clinician suspects reduced first-pass metabolism and reduced hepatic clearance. Which pharmacokinetic parameter is most affected by this condition in this patient?
    Answer: Increased bioavailability due to reduced first-pass metabolism, increasing AUC at the same oral dose This question tests the application of pharmacokinetics in clinical scenarios, specifically understanding how pharmacokinetic parameters affect drug dosing and efficacy. Pharmacokinetics involves absorption, distribution, metabolism, and excretion (ADME) of drugs. Key parameters include half-life, volume of distribution, and clearance. In this case, high first-pass drug in cirrhosis yields higher concentrations, illustrating reduced metabolism increasing bioavailability. The correct answer, A, is based on increased F raising AUC, showing exposure elevation. A common misconception is decreased bioavailability from absorption impairment, as seen in B, which fails because cirrhosis enhances systemic availability. To teach this, focus on portal shunting effects. Encourage students to model first-pass changes.
11. A 70-year-old man with atrial fibrillation is taking oral warfarin (stable INR 2.3). He begins trimethoprim-sulfamethoxazole for a urinary tract infection. Four days later, he presents with epistaxis and gingival bleeding. Labs: INR 6.1, hemoglobin 12.8 g/dL, creatinine 1.0 mg/dL, AST 28 U/L, ALT 24 U/L, albumin 4.1 g/dL. Warfarin is highly albumin-bound and primarily cleared by hepatic metabolism; its half-life is ~36 hours. The clinician suspects a drug-drug interaction affecting clearance and/or free fraction. Which of the following best describes how the pharmacokinetics of warfarin is altered in this patient?
    Answer: Enzyme inhibition decreases hepatic clearance, increasing AUC and prolonging effective half-life This question tests the application of pharmacokinetics in clinical scenarios, specifically understanding how pharmacokinetic parameters affect drug dosing and efficacy. Pharmacokinetics involves absorption, distribution, metabolism, and excretion (ADME) of drugs. Key parameters include half-life, volume of distribution, and clearance. In this case, warfarin bleeding from interaction with trimethoprim-sulfamethoxazole arises from enzyme inhibition, illustrating reduced clearance elevating INR. The correct answer, A, is based on inhibition decreasing clearance and increasing AUC, showing why anticoagulation intensifies. A common misconception is enzyme induction increasing clearance, as seen in B, which fails because this interaction inhibits metabolism. To teach this, focus on CYP interactions and monitoring. Encourage students to predict interaction outcomes using kinetic principles.
12. A 67-year-old man with CKD stage 4 is started on oral gabapentin for neuropathic pain. After 1 week, he reports profound sedation and dizziness. Labs: creatinine 2.8 mg/dL, estimated GFR 20 mL/min/1.73 m$^2$, AST 18 U/L, ALT 16 U/L. Gabapentin is not significantly metabolized and is eliminated unchanged by the kidneys; normal half-life is ~5–7 hours but increases markedly when GFR is reduced. Which of the following best describes how the pharmacokinetics of gabapentin is altered in this patient?
    Answer: Half-life is prolonged due to reduced renal clearance, increasing AUC at the same dose This question tests the application of pharmacokinetics in clinical scenarios, specifically understanding how pharmacokinetic parameters affect drug dosing and efficacy. Pharmacokinetics involves absorption, distribution, metabolism, and excretion (ADME) of drugs. Key parameters include half-life, volume of distribution, and clearance. In this case, gabapentin sedation in CKD stems from accumulation, illustrating prolonged half-life from reduced renal clearance. The correct answer, A, is based on extended half-life increasing AUC, showing why dosing must be reduced. A common misconception is shortened half-life from decreased filtration, as seen in B, which fails because reduced clearance prolongs half-life. To teach this, focus on renally cleared drugs in CKD. Encourage students to use dosing guidelines based on GFR.
13. A 57-year-old woman with rheumatoid arthritis is stable on oral methotrexate. She begins high-dose ibuprofen for pain. One week later, she develops mouth ulcers and fatigue. Labs: creatinine 1.6 mg/dL (baseline 0.9), BUN 32 mg/dL, AST 24 U/L, ALT 20 U/L, WBC 2.9 $\times 10^3$/mcL. Methotrexate is primarily renally eliminated and is secreted by renal tubules; NSAIDs can reduce renal perfusion and compete for tubular secretion, decreasing methotrexate clearance. Which of the following best describes how the pharmacokinetics of methotrexate is altered in this patient?
    Answer: Decreased renal clearance increases AUC and prolongs half-life, raising toxicity risk This question tests the application of pharmacokinetics in clinical scenarios, specifically understanding how pharmacokinetic parameters affect drug dosing and efficacy. Pharmacokinetics involves absorption, distribution, metabolism, and excretion (ADME) of drugs. Key parameters include half-life, volume of distribution, and clearance. In this case, methotrexate toxicity from ibuprofen arises from renal interactions, illustrating decreased clearance causing accumulation. The correct answer, A, is based on reduced renal clearance increasing AUC and half-life, showing myelosuppression risk. A common misconception is increased clearance decreasing AUC, as seen in B, which fails because NSAIDs impair renal function. To teach this, focus on tubular secretion competitions. Encourage students to monitor for interactions.
14. A 50-year-old man with type 2 diabetes and CKD stage 5 (on hemodialysis) develops a skin infection and is prescribed oral trimethoprim-sulfamethoxazole. Two days later he becomes lethargic and confused. Labs: creatinine 6.8 mg/dL, BUN 78 mg/dL, potassium 5.8 mmol/L, bicarbonate 18 mmol/L. The drug is partially renally eliminated and has a normal half-life of ~10 hours; in severe renal impairment, clearance falls and half-life increases substantially. Which pharmacokinetic parameter is most affected by renal failure in this patient?
    Answer: Decreased clearance leading to increased half-life and higher steady-state concentrations This question tests the application of pharmacokinetics in clinical scenarios, specifically understanding how pharmacokinetic parameters affect drug dosing and efficacy. Pharmacokinetics involves absorption, distribution, metabolism, and excretion (ADME) of drugs. Key parameters include half-life, volume of distribution, and clearance. In this case, trimethoprim-sulfamethoxazole toxicity in ESRD arises from accumulation, illustrating decreased clearance in renal failure. The correct answer, B, is based on reduced clearance increasing half-life and concentrations, showing metabolic acidosis risk. A common misconception is increased clearance reducing AUC, as seen in A, which fails because renal impairment impairs excretion. To teach this, focus on half-life changes in CKD. Encourage students to adjust for GFR.
15. A 68-year-old man with cirrhosis is started on a continuous IV infusion of a hepatically metabolized sedative. The drug has Vd 40 L and normal clearance 40 L/h (half-life $\approx 0.693\times Vd/CL \approx 0.7$ h). In this patient, clearance is estimated to be 10 L/h due to hepatic dysfunction, with Vd unchanged. No renal impairment is present. What adjustment to the dosing regimen is most appropriate given the pharmacokinetic data?
    Answer: Decrease the infusion rate to match reduced clearance and prevent a higher steady-state concentration This question tests the application of pharmacokinetics in clinical scenarios, specifically understanding how pharmacokinetic parameters affect drug dosing and efficacy. Pharmacokinetics involves absorption, distribution, metabolism, and excretion (ADME) of drugs. Key parameters include half-life, volume of distribution, and clearance. In this case, sedative infusion in cirrhosis requires adjustment for lower clearance, illustrating steady-state dependence on infusion rate and clearance. The correct answer, A, is based on decreasing rate to maintain target concentration, showing prevention of excess. A common misconception is increasing rate for reduced clearance, as seen in B, which fails because lower clearance raises steady-state levels. To teach this, focus on Css = rate/CL equation. Encourage students to calculate adjustments using kinetics.
16. A 45-year-old man with CKD stage 4 is prescribed a renally eliminated antiviral. The drug follows first-order kinetics and has Vd 30 L. In healthy adults, clearance is 6 L/h (half-life $\approx 3.5$ h). In this patient, measured clearance is 2 L/h due to reduced GFR. No hepatic disease. Which of the following best describes how the pharmacokinetics of this drug is altered in this patient?
    Answer: Half-life increases because clearance decreases while Vd remains constant This question tests the application of pharmacokinetics in clinical scenarios, specifically understanding how pharmacokinetic parameters affect drug dosing and efficacy. Pharmacokinetics involves absorption, distribution, metabolism, and excretion (ADME) of drugs. Key parameters include half-life, volume of distribution, and clearance. In this case, a patient with chronic kidney disease receiving a renally eliminated antiviral illustrates the impact of decreased clearance on half-life. The correct answer, Choice A, is based on the half-life formula (t1/2 = 0.693 * Vd / CL), showing that decreased clearance with constant Vd leads to increased half-life. A common misconception is that reduced clearance accelerates drug elimination, as seen in Choice B, which fails because reduced clearance actually prolongs the drug's presence in the plasma. To teach this, focus on renal elimination pathways and how they are impaired in kidney disease. Encourage students to calculate half-life using given parameters and apply concepts to dosing adjustments in renal impairment.
17. A 39-year-old man with bipolar disorder is taking lithium. He develops dehydration from gastroenteritis and continues his usual dose. He presents with tremor, ataxia, and confusion. Labs: creatinine 1.8 mg/dL (baseline 0.9), BUN 38 mg/dL, sodium 150 mmol/L, lithium level 2.1 mmol/L (therapeutic 0.6–1.2). Lithium is not metabolized and is eliminated by renal excretion; reduced GFR decreases clearance and prolongs half-life. How would renal impairment alter the elimination of this drug?
    Answer: Decreased renal clearance prolongs half-life, increasing steady-state concentration at the same dose This question tests the application of pharmacokinetics in clinical scenarios, specifically understanding how pharmacokinetic parameters affect drug dosing and efficacy. Pharmacokinetics involves absorption, distribution, metabolism, and excretion (ADME) of drugs. Key parameters include half-life, volume of distribution, and clearance. In this case, lithium toxicity from dehydration-induced AKI shows impaired excretion, illustrating reduced clearance in renal impairment. The correct answer, A, is based on decreased clearance prolonging half-life and raising levels, showing neurotoxicity. A common misconception is shortened half-life from reduced clearance, as seen in B, which fails because lower clearance extends half-life. To teach this, focus on hydration and monitoring in lithium use. Encourage students to correlate GFR with levels.
18. A 62-year-old man with chronic hepatitis C and decompensated cirrhosis (ascites, jaundice) is admitted for cellulitis. He is started on intravenous lidocaine for ventricular ectopy. Baseline vitals are stable. Exam shows scleral icterus and shifting dullness. Labs: total bilirubin 5.2 mg/dL, albumin 2.3 g/dL, INR 2.1, AST 88 U/L, ALT 64 U/L, creatinine 0.9 mg/dL. Lidocaine is a high hepatic extraction drug with extensive first-pass metabolism (oral bioavailability low), Vd $\approx 1.1\ \text{L/kg}$, and normal adult clearance $\approx 10\ \text{mL/min/kg}$ with half-life $\approx 1.5$ hours. Six hours after starting a continuous infusion at a standard rate, a steady-state concentration is not achieved and measured plasma concentration is 2.8 mcg/mL (target 1.5–5 mcg/mL), but by 18 hours the concentration rises to 6.2 mcg/mL with new confusion and perioral numbness. No interacting drugs are given. Given reduced hepatic blood flow and impaired metabolic capacity in cirrhosis, the team reviews that for high-extraction drugs, clearance is flow-limited and decreases with reduced hepatic perfusion, prolonging half-life and increasing accumulation during infusion. Which pharmacokinetic parameter is most affected by liver disease in this patient?
    Answer: Decreased hepatic clearance due to reduced hepatic blood flow increases half-life and accumulation This question tests the application of pharmacokinetics in clinical scenarios, specifically understanding how pharmacokinetic parameters affect drug dosing and efficacy. Pharmacokinetics involves absorption, distribution, metabolism, and excretion (ADME) of drugs. Key parameters include half-life, volume of distribution, and clearance. In this case, the patient with decompensated cirrhosis experiences lidocaine accumulation due to reduced hepatic blood flow and impaired metabolism, illustrating flow-limited clearance for high-extraction drugs. The correct answer, B, is based on decreased hepatic clearance increasing half-life and accumulation, showing why toxicity develops during infusion. A common misconception is that increased Vd from ascites speeds elimination, as seen in A, which fails because Vd affects distribution, not clearance for hepatically cleared drugs. To teach this, focus on extraction ratios and how liver disease alters them. Encourage students to analyze infusion kinetics and adjust doses in hepatic impairment.
19. A 60-year-old woman with primary biliary cholangitis and cirrhosis is started on oral morphine for severe pain. Within 24 hours she becomes increasingly sedated with shallow respirations. Exam: RR 8/min, pinpoint pupils. Labs: total bilirubin 6.0 mg/dL, albumin 2.4 g/dL, INR 2.0, creatinine 0.9 mg/dL. Morphine has significant first-pass metabolism; hepatic clearance contributes substantially to elimination, and normal half-life is ~2–3 hours. The team reviews that impaired hepatic metabolism can increase bioavailability and reduce clearance, leading to higher plasma concentrations at a given dose. Which pharmacokinetic parameter is most affected by liver disease in this patient?
    Answer: Decreased hepatic clearance and reduced first-pass metabolism increasing systemic exposure This question tests the application of pharmacokinetics in clinical scenarios, specifically understanding how pharmacokinetic parameters affect drug dosing and efficacy. Pharmacokinetics involves absorption, distribution, metabolism, and excretion (ADME) of drugs. Key parameters include half-life, volume of distribution, and clearance. In this case, the patient with cirrhosis shows morphine oversedation from increased exposure, illustrating impaired hepatic clearance and reduced first-pass. The correct answer, B, is based on decreased clearance increasing systemic exposure, showing why respiratory depression ensues. A common misconception is increased clearance reducing AUC, as seen in A, which fails because cirrhosis impairs metabolism. To teach this, focus on opioid kinetics in liver disease. Encourage students to review extraction ratios and monitor for accumulation.
20. A 66-year-old woman with chronic kidney disease (CKD) stage 4 presents with pneumonia and is started on intravenous gentamicin. She weighs 60 kg. Labs: creatinine 2.6 mg/dL, BUN 46 mg/dL, estimated GFR 22 mL/min/1.73 m$^2$, AST 24 U/L, ALT 20 U/L. Gentamicin is hydrophilic with Vd $\approx 0.25\ \text{L/kg}$ and is eliminated almost entirely by glomerular filtration; normal half-life is ~2 hours with normal renal function. Twelve hours after a standard dose, the measured concentration remains elevated. How would renal impairment alter the elimination of this drug?
    Answer: Decreased renal clearance prolongs half-life, increasing trough concentrations and accumulation risk This question tests the application of pharmacokinetics in clinical scenarios, specifically understanding how pharmacokinetic parameters affect drug dosing and efficacy. Pharmacokinetics involves absorption, distribution, metabolism, and excretion (ADME) of drugs. Key parameters include half-life, volume of distribution, and clearance. In this case, elevated gentamicin levels in CKD result from impaired excretion, illustrating reduced renal clearance. The correct answer, A, is based on decreased clearance prolonging half-life and raising troughs, showing ototoxicity risk. A common misconception is shortened half-life from reduced clearance, as seen in B, which fails because lower clearance extends half-life. To teach this, focus on GFR-drug clearance relationships. Encourage students to use nomograms for dosing.

Start this quiz